Amgen news kicks off Q3 trading: CalAmp frontrunner in first-half standings
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen teams up for Chinese joint venture
Thousand Oaks-based biotech giant Amgen has teamed up with a Chinese company for a joint venture to sell its colorectal cancer drug Vectibix there. Zhejiang Beta Pharma will be 51 percent owner of the the new firm, which will be known as Amgen-Beta Pharmaceuticals. The deal is still subject to approval from Chinese authorities. Amgen’s Read More →
Amgen shares top $100 as fears fade over biosimilars
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen shares jump on good news from melanoma drug study
[wikichart align=”right” ticker=”NASDAQ:AMGN” showannotations=”true” livequote=”true” startdate=”20-09-2012″ enddate=”20-03-2013″ width=”300″ height=”245″] Shares of Thousand Oaks-based Amgen rose in light trading on March 20 after the company announced favorable results from a drug that treats advanced melanoma. The drug, dubbed T-VEC, uses a virus to infiltrate tumors and shrink them. It achieved positive results in a large number Read More →
Amgen loses case before U.S. Supreme Court
Thousand Oaks-based Amgen has lost a case before the U.S. Supreme Court that would have made it much more difficult for shareholders of public companies to band together and sue firms when their leaders make false or misleading statements. In Amgen v. Connecticut Retirement Plans and Trust Funds, the biotech giant sought to tighten the Read More →
Amgen inks $180M nanomedicine deal
Thousand Oaks-based Amgen has entered a deal to pay up to $180.5 million for nanomedicine tumor treatments being developed by a Massachusetts company. Cambridge-based Bind Biosciences said it has entered a development agreement with Amgen for its kinase inhibitor nanomedicines for treating a range of solid tumors. The medicines are highly targeted and can be Read More →
Amgen to pay $150M for misbranding Aranesp
[Editor’s note: This story has been updated with comments from Amgen.] Biotech giant Amgen pleaded guilty Dec. 18 to a misdemeanor charge for misbranding its anemia drug Aranesp. According to a report from Bloomberg News, the Thousand Oaks-based firm agreed to pay $150 million in fines and penalties as part of the guilty plea. U.S. Read More →
